For the quarter ending 2026-03-31, TXG had $16,319K increase in cash & cash equivalents over the period. $24,523K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Rou assets impairment due to restructuring | - | 1,253 | - | - |
| Net loss | -13,470 | -16,252 | -27,472 | 180 |
| Amortization of right-of-use assets | - | 2,035 | 1,954 | 3,628 |
| Stock-based compensation expense | 22,642 | 25,219 | 25,264 | 58,635 |
| Depreciation and amortization | 9,957 | 10,065 | 10,297 | 15,837 |
| Operating lease, right-of-use asset, periodic reduction | 1,953 | - | - | - |
| Fair value adjustments on contingent consideration | 57 | -272 | -1,135 | - |
| Asset and lease impairment charges | 0 | 0 | 700 | 114 |
| Realized loss on marketable securities | - | 0 | 0 | 0 |
| Other | -193 | -393 | -434 | -926 |
| Accounts receivable | -7,980 | 3,232 | -6,629 | -37,917 |
| Other receivables | -18,129 | -17,334 | -16,276 | 68,484 |
| Inventory | -2,702 | -5,582 | -7,287 | -15,084 |
| Prepaid expenses and other current assets | -1,945 | 2,985 | -1,383 | 741 |
| Other noncurrent assets | -282 | 1,601 | 149 | -2,439 |
| Accounts payable | 4,782 | -5,418 | -196 | 3,488 |
| Accrued compensation and other related benefits | -20,956 | 5,363 | 10,101 | -7,817 |
| Deferred revenue | 77 | 1,394 | -190 | -458 |
| Accrued contingent consideration and assumed liabilities | -613 | - | - | - |
| Accrued expenses and other current liabilities | -6,136 | 4,786 | -7,048 | -2,891 |
| Operating lease liability | -2,854 | -2,720 | -2,604 | -4,986 |
| Other noncurrent liabilities | -50 | 75 | 281 | 1,040 |
| Net cash provided by operating activities | 26,120 | 40,777 | 43,214 | 52,059 |
| Purchase of intangible assets | - | 0 | 0 | 0 |
| Asset acquisition, net | - | 652 | 8,616 | - |
| Proceeds from sales of marketable securities | - | 0 | 0 | 0 |
| Purchases of property and equipment | 1,597 | 1,777 | 687 | 3,471 |
| Purchases of marketable securities | 24,714 | 24,576 | 49,498 | 49,361 |
| Proceeds from maturities of marketable securities | 25,000 | 25,200 | 50,000 | 50,000 |
| Net cash used in investing activities | -1,311 | -1,805 | -8,801 | -2,832 |
| Issuance of common stock from exercise of stock options | 273 | 2,242 | 617 | 3,944 |
| Payments on technology license financing arrangement | - | 0 | - | - |
| Payment of contingent consideration | 8,690 | - | - | - |
| Net cash provided by (used in) financing activities | -8,417 | 2,242 | 617 | 3,944 |
| Effect of exchange rates changes on cash and cash equivalents | -73 | 43 | -33 | 474 |
| Net increase in cash and cash equivalents | 16,319 | 41,257 | 34,997 | 53,645 |
| Cash and cash equivalents at beginning of period | 473,966 | 432,709 | 344,067 | - |
| Cash and cash equivalents at end of period | 490,285 | 473,966 | 432,709 | - |
10x Genomics, Inc. (TXG)
10x Genomics, Inc. (TXG)